Literature DB >> 26102514

Attention-Deficit Hyperactivity Disorder and Long-QT Syndrome: Risky Business.

Jonathan R Kaltman1,2, Charles I Berul1.   

Abstract

Entities:  

Keywords:  adrenergic side effect; attention-deficit hyperactivity disorder; congenital arrhythmia; long-QT syndrome; stimulants

Mesh：

Substances：

Year:  2015        PMID： 26102514      PMCID： PMC4607628          DOI： 10.1111/jce.12744

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN： 1045-3873


× No keyword cloud information.
  24 in total

1.  ADHD drugs and cardiovascular risk.

Authors:  Steven E Nissen
Journal:  N Engl J Med       Date:  2006-03-20       Impact factor: 91.245

2.  American Academy of Pediatrics/American Heart Association clarification of statement on cardiovascular evaluation and monitoring of children and adolescents with heart disease receiving medications for ADHD: May 16, 2008.

Authors: 
Journal:  J Dev Behav Pediatr       Date:  2008-08       Impact factor: 2.225

3.  Cardiovascular events and death in children exposed and unexposed to ADHD agents.

Authors:  Hedi Schelleman; Warren B Bilker; Brian L Strom; Stephen E Kimmel; Craig Newcomb; James P Guevara; Gregory W Daniel; Mark J Cziraky; Sean Hennessy
Journal:  Pediatrics       Date:  2011-05-16       Impact factor: 7.124

4.  Long-QT Syndrome and Therapy for Attention Deficit/Hyperactivity Disorder.

Authors:  Claire Zhang; Valentina Kutyifa; Arthur J Moss; Scott McNitt; Wojciech Zareba; Elizabeth S Kaufman
Journal:  J Cardiovasc Electrophysiol       Date:  2015-08-06

5.  ADHD drugs and serious cardiovascular events in children and young adults.

Authors:  William O Cooper; Laurel A Habel; Colin M Sox; K Arnold Chan; Patrick G Arbogast; T Craig Cheetham; Katherine T Murray; Virginia P Quinn; C Michael Stein; S Todd Callahan; Bruce H Fireman; Frank A Fish; Howard S Kirshner; Anne O'Duffy; Frederick A Connell; Wayne A Ray
Journal:  N Engl J Med       Date:  2011-11-01       Impact factor: 91.245

6.  Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing.

Authors:  Victoria L Vetter; Josephine Elia; Christopher Erickson; Stuart Berger; Nathan Blum; Karen Uzark; Catherine L Webb
Journal:  Circulation       Date:  2008-04-21       Impact factor: 29.690

7.  Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database.

Authors:  Suzanne McCarthy; Noel Cranswick; Laura Potts; Eric Taylor; Ian C K Wong
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

8.  Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder.

Authors:  Almut G Winterstein; Tobias Gerhard; Jonathan Shuster; Michael Johnson; Julie M Zito; Arwa Saidi
Journal:  Pediatrics       Date:  2007-12       Impact factor: 7.124

9.  Cardiovascular safety of central nervous system stimulants in children and adolescents: population based cohort study.

Authors:  Almut G Winterstein; Tobias Gerhard; Paul Kubilis; Arwa Saidi; Stephan Linden; Stephen Crystal; Julie Zito; Jonathan J Shuster; Mark Olfson
Journal:  BMJ       Date:  2012-07-18

10.  Analysis of cardiac autonomic modulation of children with attention deficit hyperactivity disorder.

Authors:  Tatiana Dias de Carvalho; Rubens Wajnsztejn; Luiz Carlos de Abreu; Luiz Carlos Marques Vanderlei; Moacir Fernandes Godoy; Fernando Adami; Vitor E Valenti; Carlos B M Monteiro; Claudio Leone; Karen Cristina da Cruz Martins; Celso Ferreira
Journal:  Neuropsychiatr Dis Treat       Date:  2014-04-11       Impact factor: 2.570
View more
  1 in total

1.  Selective Effects of Methylphenidate on Attention and Inhibition in 22q11.2 Deletion Syndrome: Results From a Clinical Trial.

Authors:  Johanna Maeder; Valentina Mancini; Corrado Sandini; Fiona Journal; Maude Schneider; Matthias Kliegel; Stephan Eliez
Journal:  Int J Neuropsychopharmacol       Date:  2022-03-17       Impact factor: 5.176
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.